Categorie: Știri

Sage Therapeutics încetează dezvoltarea dalzanemdor în HD

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Puterea parteneriatului. Elveția și China dau un exemplu.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Lives Lives - o nouă carte care prezintă poveștile oamenilor afectați de HD din întreaga lume

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics anunță o finanțare de 35 de milioane de lire sterline pentru a promova un nou medicament destinat inhibării expansiunii somatice în boala Huntington

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

FDA acordă desemnarea Fast Track pentru programul PTC518 pentru boala Huntington

PTC518 este un medicament oral care reduce producția proteinei Huntingtin mutante care cauzează progresia bolii. Programele cu desemnare Fast Track pot beneficia de interacțiuni timpurii cu FDA și pot fi [...]

Pridopidina de la Prilenia pentru boala Huntington a fost acceptată pentru revizuirea autorizației europene de introducere pe piață

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

IROS, Prilenia și International Huntington's Disease Association colaborează la primul studiu privind boala Huntington (HD) din regiunea MENA

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure anunță actualizarea datelor intermediare pozitive care demonstrează încetinirea progresiei bolii în studiile de fază I/II ale AMT-130 pentru HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” […]

Wave Life Sciences anunță rezultate pozitive din studiul de fază 1b/2a SELECT-HD cu prima demonstrație clinică a reducerii alelei de huntingtină mutantă selectivă în boala Huntington

Today, Wave Life Sciences announced positive results from SELECT-HD, our Phase 1b/2a placebo-controlled trial evaluating the investigational therapy WVE-003. These results demonstrate that WVE-003 selectively lowers toxic, mutant huntingtin (mHTT) […]

PTC a anunțat astăzi rezultate promițătoare la 12 luni de la studiul de fază 2 PIVOT-HD al PTC518 oral.  

At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where […]